Prospective Randomized Trial Between Two Doses of Granulocyte Colony-Stimulating Factor After Ifosfamide, Carboplatin, and Etoposide in Children With Recurrent or Refractory Solid Tumors: A Children's Cancer Group Report
Mitchell S. Cairo(New York Medical College), Gregory H. Reaman(National Cancer Institute), Judith K. Sato(City Of Hope National Medical Center), Julie Blatt(Center for Cancer and Blood Disorders), Wen Liu‐Mares(Children's Oncology Group), Bruce R. Blazar(University of Minnesota Medical Center), Sharon Frierdich(University of Wisconsin–Madison), Mark Krailo(Arcadia), Madeline Bauer(University of Southern California), Violet Shen(Ruhr University Bochum), James S Miser(City of Hope)
The American journal of pediatric hematology/oncology
January 1, 2001
Cited by 56
Related Papers
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
|Nature Medicine|2006|3.6k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724